Navigation Links
Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Date:12/14/2007

SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(R) Tissue of Origin Test is the focus of a study published in the January issue of The Journal of Molecular Diagnostics. Pathwork's genomics-based test is designed to help determine a tumor's origin so that tissue-specific management can begin. The study, performed by principal investigator Federico A. Monzon, M.D., and colleagues from the University of Pittsburgh, Virginia Commonwealth University and Stanford University, examined the analytical performance characteristics and reproducibility of the Tissue of Origin Test.

There are an estimated 200,000 cancer patients with an uncertain primary diagnosis on their cancers each year in the U.S.(1),(2),(3) These people may benefit from additional diagnostic information to determine the tissue of origin for their cancer. One study showed that, in such cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.

The Pathwork Tissue of Origin Test measures the expression of more than 1600 genes and compares a tumor's gene expression "signature" against those of 15 known tissue types. The test uses microarray technology, which enables large numbers of genes to be evaluated at the same time, using the proven, commercially available Affymetrix microarray platform.

In the study, 60 archived tissue specimens from poorly and undifferentiated tumors (metastatic and primary) were analyzed at four laboratories representing a wide range of pre-analytical conditions. Reproducibility was analyzed by cross-wise comparisons of all 4 sites. Cross-laboratory comparisons, performed using a variety of measures, showed highly reproducible results betwe
'/>"/>

SOURCE Pathwork Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Transparency Market Research has published ... Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, ... Volume, Share, Growth, Trends and Forecast 2014 - 2022 ... published by Transparency Market Research " Non-invasive Prenatal Testing ... Trends and Forecast 2014 - 2022 ", the global ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... YORK, Feb. 1, 2011 Reportlinker.com announces that a ... Pen Injectors ... of an increasing number of drugs in pre-filled disposable ... pens at the expense of other drug delivery methods ...
... Reportlinker.com announces that a new market research report ... Fludarabine - Comprehensive patent search ... with the industry benchmark in comprehensive patent information. ... professional patent search performed by our expert team, ...
Cached Medicine Technology:Reportlinker Adds Fludarabine - Comprehensive Patent Search 2Reportlinker Adds Fludarabine - Comprehensive Patent Search 3Reportlinker Adds Fludarabine - Comprehensive Patent Search 4
(Date:8/4/2015)... Los Angeles, California (PRWEB) , ... August 04, ... ... bearing drawer slides to Los Angeles commercial customers. Finding reliable hardware can ... create unfortunate liabilities. When putting an office together or designing a new ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide ... Power Products is expanding its reach in Texas. Effective July 1st of this ... North Texas generator division. With the North Texas acquisition, Worldwide Power Products ...
(Date:8/4/2015)... ... 2015 , ... Many men are confused about the safety of testosterone replacement ... as a voice of authority for men seeking accurate information about testosterone. , ... and expertise in the safe and effective treatment of low testosterone. In recent years, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, ... Google” before calling a physician. In an effort to share more and better ... provider in Pennsylvania to publicly share patient satisfaction ratings and comments about its ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... mesothelioma patients whose cancer has come back: Retreatment may be a viable option. ... to read it now. , According to surgeons at the University of ...
Breaking Medicine News(10 mins):Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:North Texas Acquisition Press Release 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2
... MYL ),today announced that in accordance with its 2.139 ... dividend of $15.53,per share (based on the annual dividend rate ... the time period from the date of,issuance to February 15, ... of record as of February 1, 2008., Mylan Inc. ...
... 30 OxySure(R) Systems, Inc.,announced today that the ... World,s,Best Technologies (WBT) in 2008. OxySure(R) has developed ... two inert, proprietary,powders. The company,s inclusion into the ... Generator, Model 615, which OxySure(R) launched,in late 2007. ...
... safe dosages of the isotope astatine-211 for patients ... to find that not only was the isotopes ... damaging sensitive healthy brain cells, but the patients ... much as five times or more cell-killing efficiency ...
... Low in Seasonal Illness affects sales of Cough ... Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an over-the-counter ... consumers with "Better Ways to Get,Better(R)," today announced ... nine months ended December 31, 2007. Third quarter ...
... Shares at the Annual Meeting of ... Stockholders on March 11, 2008), BEDFORD, Mass., ... technologies company specializing in,diagnostics imaging systems and interventional devices dedicated to ... Directors,has approved a two-for-one stock split, to be effected in the ...
... preserving Blue Cross,s nonprofit mission gives Michigan ... LANSING, Mich., Jan. 30 Creation of ... people rejected by,commercial insurers and HMOs because of ... the Michigan Senate Health Policy Committee,today. The Senate ...
Cached Medicine News:Health News:OxySure(R) Systems, Inc. Named to 2008 World's Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks 2Health News:Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients 2Health News:Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients 3Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 2Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 3Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 4Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 5Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 6Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 7Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 8Health News:Hologic Announces Two-For-One Stock Split 2Health News:Hologic Announces Two-For-One Stock Split 3Health News:Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over 2Health News:Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over 3
Algerbrush II corneal rust ring remover battery powered...
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
... TW full diameter trial lens set has ... twenty years. While maintaining only the highest ... the Marco 35-6 TW trial lens set ... by adhering to strict industry guidelines, and ...
Khosla Mini Non-Illuminated Trial Lens Set, With Lenses Mounted...
Medicine Products: